Rhythm Pharmaceuticals
Sells setmelanotide (Imcivree) for rare genetic and hypothalamic obesity.
Share price
$90.78
Down 9.4% over 12 monthsWhat analysts expect
Buy
Buy80%
Hold15%
Sell5%
Price target for the next 12 months
$143Up 62% compared with the current price
Price now $88.23Average targetLowest $120 to highest $160
22 analysts. Source: MarketBeat, 20 Oct 2026. Targets are opinions and are often wrong.
Business
- Yearly revenue
- $240M
- Yearly profit
- Loss $210M
- Company value
- $6.3B
Revenue and profit for the last twelve months reported.
Peptides in this book
- SetmelanotidePrescription
Recent news
- 2026-09-22 Health Canada approves Imcivree for acquired hypothalamic obesity from age 4 GlobeNewswire
- 2026-08-24 Japan approves Imcivree for acquired hypothalamic obesity GlobeNewswire
- 2026-09-10 Rhythm announces new data presentations at European paediatric endocrinology meeting GlobeNewswire
Prices are delayed and figures rounded. Not investment advice.